Levosimendan Fresenius Kabi (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contraction without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers both preload and afterload.

The dosage regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal or hepatic function. The prescriber sets the infusion rate and duration according to approved guidelines and individual needs.

The safety of levosimendan in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan sensitizes the heart to existing calcium, offering improved contractility with a lower risk of calcium‑related toxicity. It also provides vasodilatory effects, which many other inotropes lack, making it a distinct therapeutic option for acute heart failure.

Levosimendan injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Levosimendan is given as an intravenous infusion. The preparation is added to a compatible infusion fluid and administered under continuous monitoring of blood pressure, heart rate, and cardiac rhythm, following the dosing instructions provided by the prescribing clinician.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for these events, especially during the initial infusion period.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure < 90 mmHg), significant ventricular arrhythmias, or known hypersensitivity to the drug or any of its excipients. Caution is also advised in patients with severe hepatic impairment.